ASA Monitor April 2024, Vol. 88, 14.
Lower risk of suicidal ideation with semaglutide
A study funded by the National Institutes of Health (NIH) has found that semaglutide, an FDA-approved medication for obesity and type 2 diabetes, is associated with a 49%-73% lower risk of first-time or recurring suicidal ideations compared to other medications with different mechanisms for controlling obesity and diabetes. The research analyzed electronic health records of over 240,000 obese or overweight patients and nearly 1.6 million patients with type 2 diabetes. The study contradicts anecdotal reports linking semaglutide to suicidal thoughts and supports its safety in this regard. Patients prescribed semaglutide for weight loss had a lower risk of suicidal ideations compared to those on other weight loss medications. Similarly, in patients with type 2 diabetes, semaglutide showed a lower risk of first-time suicidal ideation, even at longer follow-up durations. The researchers recommend further studies to explore potential longer-term associations and evaluate semaglutide’s impact on suicidal ideations in other populations.
Source: asamonitor.pub/48VkIby
Leave a Reply
You must be logged in to post a comment.